Side Effects Of Drugs Annual Volume 28 at Meripustak

Side Effects Of Drugs Annual Volume 28

Books from same Author: Jeffrey K Aronson

Books from same Publisher: ELSEVIER

Related Category: Author List / Publisher List


  • Retail Price: ₹ 32923/- [ 25.00% off ]

    Seller Price: ₹ 24692

Sold By: MeriPustak      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 25.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 25.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Jeffrey K Aronson
    PublisherELSEVIER
    ISBN9780444515711
    Pages694
    BindingSoftbound
    LanguageEnglish
    Publish YearDecember 2005

    Description

    ELSEVIER Side Effects Of Drugs Annual Volume 28 by Jeffrey K Aronson

    Volume 28 in the series of Side Effects of Drugs Annuals (http://www.elsevier.com/locate/series/seda) continues to serve its primary goal: to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has reviewed new data and trends by selecting from the year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is unproven or misleading. The use of the book is enhanced by separate indexes, allowing the reader to access the text via drug name, adverse effect, or drug interaction. The current annual includes an essay by the editor, Dr Jeffrey Aronson, entitled 'Classifying Drug Adverse Reactions in the 21st Century.' In it he describes how the modern approach to classifying adverse drug reactions takes into account the dose that causes the reaction, the time-course of the reaction, and the susceptibility factors that increase the individual patient's risk, and shows how this analysis can facilitate regulatory decision making.